In the News
Alzheimer’s Research and Treatment Center
Lecanemab FDA Approval.
Dr. Watson, the world’s leading investigator for the Lecanemab compound, letter and statement on the FDA approval of Lecanemab. We are all ecstatic here at ARTC with the approval of the Lecanemab. This is the first disease modifying treatment to be approved anywhere in the world. This approval...
Lecanemab in Early Alzheimer’s Disease.
Dr. David Watson of ARTC is one of the primary author's of this article on Lecanemab and Alzheimer's Disease. The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal...
Positive Topline Results from the Clinical Trial of Lecanemab.
In September 2022, Eisai Co. and Biogen Inc. announced very positive topline results from the clinical trial of Lecanemab, an investigational treatment for mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s Disease. Eisai will be presenting the complete Clarity AD results at...
A Breakthrough in Alzheimer’s Disease.
Dr. Watson at ARTC is the world’s leading investigator for the Lecanemab compound. On September 27, 2022 Eisai Co.,LTD and Biogen Inc. released the following statement.